Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    124
    ...
ATC Name B/G Ingredients Dosage Form Price
N02CC04 MAXALT B Rizatriptan (benzoate) - 10mg Tablet 439,436 L.L
C09CA04 IRBESARTAN ARROW G Irbesartan - 150mg 150mg Tablet 1,326,373 L.L
C10AA07 PMS-ROSUVASTATIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 564,414 L.L
J01CR02 MOXICLAV G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet 430,030 L.L
N02CC04 RIZATRIPTAN ARROW G Rizatriptan - 10mg 10mg Tablet 1,182,581 L.L
L01EA02 SPRYCEL B Dasatinib - 50mg 50mg Tablet 212,274,841 L.L
L02BA01 TAMOXIFENE BIOGARAN G Tamoxifen (citrate) - 10mg 10mg Tablet 415,247 L.L
M01AB05 REMETHAN G Diclofenac sodium - 50mg 50mg Tablet 196,201 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet L.L
L01EA02 APO-DASATINIB G Dasatinib - 50mg 50mg Tablet 71,323,688 L.L
N05AX12 ABIPREX 10 G Aripiprazole - 10mg 10mg Tablet 1,075,074 L.L
C03EA01 MODURETIC B Hydrochlorothiazide - 50mg, Amiloride HCl - 5mg Tablet 798,398 L.L
L02BA01 TAMOXIFENE BIOGARAN G Tamoxifen (citrate) - 20mg 20mg Tablet 858,715 L.L
N05AX12 ARIPIPAN G Aripiprazole - 10mg 10mg Tablet 839,902 L.L
C10AA07 ROVASTIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 560,574 L.L
M05BB03 FOSAVANCE B Alendronic acid (sodium alendronate) - 70mg, Colecalciferol - 5600IU Tablet 1,988,887 L.L
N05AX12 ATYPRAL G Aripiprazole - 10mg 10mg Tablet 712,237 L.L
C09CA04 CONVERIUM G Irbesartan - 300mg 300mg Tablet 585,915 L.L
M05BB03 ACIDE ALENDRONIQUE/ VITAMINE D3 BGR G Alendronic acid - 70mg, Colecalciferol - 5600UI Tablet 815,712 L.L
N05AX12 JOSWE ARIPAL 10 G Aripiprazole - 10mg 10mg Tablet 2,210,621 L.L
N07CA01 BETASERC B Betahistine dihydrochloride - 16mg 16mg Tablet 1,623,708 L.L
L01EA02 APO-DASATINIB G Dasatinib - 20mg 20mg Tablet 57,771,855 L.L
N03AA02 GARDENAL B Phenobarbital - 100mg 100mg Tablet 120,946 L.L
N05AX12 PIRIFY G Aripiprazole - 10mg 10mg Tablet 795,555 L.L
C09CA04 IRBESARTAN ARROW G Irbesartan - 300mg 300mg Tablet 470,345 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 5mg 5mg Tablet 1,635,456 L.L
N05AX12 XALIPRO G Aripiprazole - 10mg 10mg Tablet 2,123,271 L.L
C09CA04 IRBESARTAN ARROW G Irbesartan - 300mg 300mg Tablet 1,326,373 L.L
N07CA01 VASOSERC FORTE G Betahistine dihydrochloride - 16mg 16mg Tablet 944,529 L.L
C09CA04 IRTAN G Irbesartan - 300mg 300mg Tablet 554,175 L.L
    ...
    124
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026